Eccogene nabs $25M Series B for GLP-1 and a NASH drug candidate, as competitors lap the China biotech
An early-stage China biotech hopes to break into the GLP-1 race for obesity and diabetes as heavyweights dominate the field, with Novo Nordisk already touting Phase III data on its oral GLP-1 and Eli Lilly and Pfizer nearing their big days.
Shanghai- and Boston-based Eccogene said Monday it has raised about $25 million, or CNY 180 million, in Series B financing as it moves through a Phase I study of its small molecule GLP-1 receptor agonist and takes its NASH and lipid disorders drug candidate through early-stage testing as well.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
